- Home
- TNGX vs CANG Comparison
TNGX vs CANG Comparison
Compare TNGX & CANG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- CANG
- Stock Information
- Founded
- TNGX 2014
- CANG 2010
- Country
- TNGX United States
- CANG Hong Kong
- Employees
- TNGX N/A
- CANG N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- CANG Computer Software: Prepackaged Software
- Sector
- TNGX Health Care
- CANG Technology
- Exchange
- TNGX Nasdaq
- CANG Nasdaq
- Market Cap
- TNGX 1.0B
- CANG 811.9M
- IPO Year
- TNGX N/A
- CANG 2018
- Fundamental
- Price
- TNGX $7.99
- CANG $3.46
- Analyst Decision
- TNGX Strong Buy
- CANG Strong Buy
- Analyst Count
- TNGX 6
- CANG 1
- Target Price
- TNGX $10.80
- CANG $8.00
- AVG Volume (30 Days)
- TNGX 4.3M
- CANG 399.7K
- Earning Date
- TNGX 11-04-2025
- CANG 11-04-2025
- Dividend Yield
- TNGX N/A
- CANG N/A
- EPS Growth
- TNGX N/A
- CANG N/A
- EPS
- TNGX N/A
- CANG N/A
- Revenue
- TNGX $66,501,000.00
- CANG $398,195,540.00
- Revenue This Year
- TNGX $20.41
- CANG $514.68
- Revenue Next Year
- TNGX N/A
- CANG $18.40
- P/E Ratio
- TNGX N/A
- CANG N/A
- Revenue Growth
- TNGX 53.29
- CANG 380.74
- 52 Week Low
- TNGX $1.03
- CANG $2.80
- 52 Week High
- TNGX $9.70
- CANG $9.66
- Technical
- Relative Strength Index (RSI)
- TNGX 49.39
- CANG 34.62
- Support Level
- TNGX $7.12
- CANG $3.82
- Resistance Level
- TNGX $8.17
- CANG $4.34
- Average True Range (ATR)
- TNGX 0.74
- CANG 0.21
- MACD
- TNGX -0.07
- CANG -0.06
- Stochastic Oscillator
- TNGX 45.74
- CANG 13.95
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.
About CANG Cango Inc. each representing two (2)
Cango Inc through its subsidiaries, variable interest entities (VIEs), and subsidiaries of the VIEs, are principally engaged in the bitcoin mining business, and the automobile trading transaction, automotive financing facilitation, and aftermarket service facilitation businesses (collectively, the automobile and related businesses). The Company conducts the bitcoin mining business mainly through its subsidiaries, and the automobile and associated businesses are conducted through the Company's VIEs and the subsidiaries of the VIEs. The company derives the majority of its revenue from the bitcoin mining business.